+

DE602007011415D1 - Verbesserte protofibrilselektive antikörper und deren verwendung - Google Patents

Verbesserte protofibrilselektive antikörper und deren verwendung

Info

Publication number
DE602007011415D1
DE602007011415D1 DE602007011415T DE602007011415T DE602007011415D1 DE 602007011415 D1 DE602007011415 D1 DE 602007011415D1 DE 602007011415 T DE602007011415 T DE 602007011415T DE 602007011415 T DE602007011415 T DE 602007011415T DE 602007011415 D1 DE602007011415 D1 DE 602007011415D1
Authority
DE
Germany
Prior art keywords
protefibrilselective
antibodies
improved
disease
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007011415T
Other languages
English (en)
Inventor
Paer Gellerfors
Lars Lannfelt
Dag Sehlin
Pettersson Frida Ekholm
Hillevi Englund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioarctic AB
Original Assignee
BIOARTIC NEUROSCIENCE AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38522718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602007011415(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BIOARTIC NEUROSCIENCE AB filed Critical BIOARTIC NEUROSCIENCE AB
Publication of DE602007011415D1 publication Critical patent/DE602007011415D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
DE602007011415T 2006-03-23 2007-03-23 Verbesserte protofibrilselektive antikörper und deren verwendung Active DE602007011415D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0600662 2006-03-23
SE0602591 2006-11-30
PCT/SE2007/000292 WO2007108756A1 (en) 2006-03-23 2007-03-23 Improved protofibril selective antibodies and the use thereof

Publications (1)

Publication Number Publication Date
DE602007011415D1 true DE602007011415D1 (de) 2011-02-03

Family

ID=38522718

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007011415T Active DE602007011415D1 (de) 2006-03-23 2007-03-23 Verbesserte protofibrilselektive antikörper und deren verwendung

Country Status (27)

Country Link
US (2) US8025878B2 (de)
EP (2) EP2325209A3 (de)
JP (1) JP5033868B2 (de)
KR (1) KR101413615B1 (de)
CN (1) CN101421303B (de)
AT (1) ATE492561T1 (de)
AU (1) AU2007227813B2 (de)
BR (1) BRPI0709050B1 (de)
CA (1) CA2630344C (de)
CY (1) CY1111337T1 (de)
DE (1) DE602007011415D1 (de)
DK (1) DK2004688T4 (de)
FI (1) FIC20250030I1 (de)
HR (1) HRP20110203T4 (de)
HU (1) HUS2500037I1 (de)
IL (1) IL191331A (de)
MX (1) MX2008012223A (de)
MY (1) MY169492A (de)
NL (1) NL301343I2 (de)
NO (2) NO347079B1 (de)
NZ (1) NZ567888A (de)
PL (1) PL2004688T5 (de)
RS (1) RS51723B2 (de)
RU (1) RU2429244C2 (de)
SI (1) SI2004688T2 (de)
WO (1) WO2007108756A1 (de)
ZA (1) ZA200805805B (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002003911A2 (en) 2000-07-07 2002-01-17 Lars Lannfelt Prevention and treatment of alzheimer's disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
EP1954718B1 (de) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a-globulomer-antikörper, antigen bindende gruppen davon, entsprechende hybridome, nukleinsäuren, vektoren, wirtszellen, verfahren zur herstellung dieser antikörper, zusammensetzungen, die diese antikörper enthalten, verwendungen dieser antikörper und verfahren zur verwendung dieser antikörper
JP5033868B2 (ja) 2006-03-23 2012-09-26 バイオアークティック ニューロサイエンス アーベー 改良型プロトフィブリル選択的抗体及びその使用
EP2006381B1 (de) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Verfahren zur kontrolle der blut-pharmakokinetik von antikörpern
DK2047863T3 (da) 2006-06-08 2013-09-16 Chugai Pharmaceutical Co Ltd Middel til forebyggelse eller behandling af inflammatoriske sygdomme
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
ES2610474T3 (es) 2007-01-11 2017-04-27 Michael Bacher Diagnóstico y tratamiento de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas causantes de demencia
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
ES2566957T3 (es) 2007-09-26 2016-04-18 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
SI2238166T1 (sl) 2007-10-05 2014-03-31 Genentech, Inc. Uporaba protitelesa proti amiloidu beta pri očesnih bolezni
ME01026B (me) * 2007-11-16 2012-10-20 Univ Rockefeller Antitijela specifična za protofibrilni oblik beta-amiloid proteina
JP5682995B2 (ja) * 2007-12-05 2015-03-11 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
JP5113853B2 (ja) * 2008-02-08 2013-01-09 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
TR201901497T4 (tr) 2008-04-29 2019-02-21 Bioarctic Ab Alfa-sinüklein ile ilişkili bozukluklar için terapötik ve teşhis yöntemlerinde kullanıma yönelik antikorlar ve aşılar.
US9085614B2 (en) * 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
NZ591187A (en) * 2008-08-20 2012-07-27 Probiodrug Ag Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (mcp-1 n1pe)
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
EP2409991B1 (de) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Variante einer konstanten antikörperregion
DK2419447T3 (en) 2009-04-17 2017-09-25 Immunas Pharma Inc ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMER AND USE THEREOF
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
ES2864049T3 (es) * 2009-06-29 2021-10-13 Bioarctic Ab Anticuerpos selectivos para protofibrillas/oligómeros de amiloide-P truncado en el extremo N
EP2273273A1 (de) * 2009-07-11 2011-01-12 Rheinische Friedrich-Wilhelms-Universität Bonn Inhibitoren der Nitrierung von Amyloid-ß-Peptiden und ihre Verwendung bei der Diagnose und Behandlung von Morbus Alzheimer
US8613924B2 (en) * 2009-08-06 2013-12-24 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
WO2011016238A1 (en) 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
ES2734886T3 (es) * 2009-11-24 2019-12-12 Alethia Biotherapeutics Inc Anticuerpos anti-clusterina y fragmentos de unión a antígeno y su uso para reducir el volumen tumoral
NO2539366T3 (de) 2010-02-26 2018-04-07
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2576617B1 (de) 2010-06-04 2016-04-27 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin MONOKLONALE ANTIKÖRPER, DIE AUF Aß-OLIGOMERE ZIELEN
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
WO2012051498A2 (en) 2010-10-15 2012-04-19 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
PT3604339T (pt) 2011-01-14 2021-04-13 Univ California Anticorpos terapêuticos contra a proteína ror-1 e métodos para utilização dos mesmos
EP2497782A1 (de) 2011-03-08 2012-09-12 Alzinova AB Anti-Oligomer-Antikörper und deren Verwendungen
EA037797B1 (ru) 2011-10-25 2021-05-21 Протена Байосайенсиз Лимитед Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
JP2013159596A (ja) * 2012-02-08 2013-08-19 Nihon Univ β−アミロイド前駆体タンパク質のマイクロ凝集体に特異的なモノクローナル抗体
NZ626742A (en) 2012-02-22 2016-06-24 Alethia Biotherapeutics Inc Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
NZ715455A (en) 2013-07-09 2021-12-24 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
BR112016005408B1 (pt) 2013-09-13 2023-03-21 Beigene Switzerland Gmbh Anticorpos anti-pd1, f(ab) ou f(ab)2 e uso referido anticorpo para tratamento de cancer ou infecção viral
LT3071597T (lt) * 2013-11-21 2020-10-12 F. Hoffmann-La Roche Ag Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
KR102130600B1 (ko) 2014-07-03 2020-07-08 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
PE20170768A1 (es) * 2014-07-10 2017-07-04 Eisai Randd Man Co Ltd Anticuerpos de union a protofibrillas ab mejorados
NZ728688A (en) 2014-07-22 2023-06-30 Cb Therapeutics Inc Anti-pd-1 antibodies
EP3177649B1 (de) 2014-08-05 2024-02-28 Apollomics Inc. Anti-pd-l1-antikörper
WO2016073685A1 (en) 2014-11-05 2016-05-12 Annexon, Inc. Humanized anti-complement factor c1q antibodies and uses thereof
WO2016100615A2 (en) * 2014-12-18 2016-06-23 The University Of Chicago Methods and composition for neutralization of influenza
TW202327654A (zh) 2015-04-14 2023-07-16 日商中外製藥股份有限公司 含有il-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物
CA2991856A1 (en) 2015-07-21 2017-01-26 Bioarctic Neuroscience Ab Method for treatment of traumatic brain injury targeting aggregated peptides
WO2017091719A1 (en) 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
JP2017132742A (ja) * 2016-01-29 2017-08-03 国立大学法人 大分大学 Ａβオリゴマー特異的抗体の新規薬理用途
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
SG11201810801QA (en) * 2016-07-14 2019-01-30 Bioarctic Ab Brain delivery protein
HUE065528T2 (hu) 2016-08-19 2024-06-28 Beigene Switzerland Gmbh Zanubrutinib kombinációja anti-CD20 vagy anti-PD-1 antitesttel rák kezelésében történõ alkalmazásra
US20200055917A1 (en) 2016-09-27 2020-02-20 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules
CN117244056A (zh) * 2016-10-27 2023-12-19 卫材研究发展管理有限公司 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物
EP3573989A4 (de) 2017-01-25 2020-11-18 Beigene, Ltd. Kristalline formen von (s)-7-(1-(but-2-ynoyl)-piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-carboxamid, herstellung und verwendungen davon
KR102757960B1 (ko) 2017-06-26 2025-01-22 베이진 엘티디 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
EP3624842A4 (de) * 2017-06-29 2021-04-07 The Trustees Of Columbia University In The City Of New York Chimäre antikörper zur behandlung von amyloidablagerungskrankheiten
US12227567B2 (en) 2017-07-25 2025-02-18 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
US11708423B2 (en) 2017-09-26 2023-07-25 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules and methods of use
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
US20210032351A1 (en) * 2017-12-13 2021-02-04 Xdcexplorer (Shanghai) Co., Ltd. Egfrviii antibody and conjugate, and preparation method and use thereof
WO2019191332A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
JP7444781B2 (ja) 2018-03-28 2024-03-06 セロ・セラピューティクス・インコーポレイテッド 細胞免疫療法組成物およびその使用
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
MY203453A (en) 2018-07-17 2024-06-28 Shanghai hengrui pharmaceutical co ltd Anti-abeta antibody, antigen-binding fragment thereof and application thereof
BR112021001272A2 (pt) * 2018-07-24 2021-04-27 Eisai R&D Management Co., Ltd. métodos de tratamento e prevenção de doença de alzheimer
CA3156713A1 (en) 2019-11-20 2021-05-27 Daisuke Kameoka Antibody-containing preparation
WO2021155112A1 (en) * 2020-01-29 2021-08-05 The Trustees Of The University Of Pennsylvania Compositions and methods of t cell receptor vb family member targeting for the treatment of t cell associated disease
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
EP4172199B1 (de) 2020-06-26 2025-05-14 BioArctic AB Alpha-synuklein-protofibrill-bindende antikörper
JP2024500447A (ja) * 2020-12-16 2024-01-09 コグネクスト ダイアグノスティックス エルエルシー アルツハイマー病及び他の神経障害の診断方法
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
JP2024522627A (ja) 2021-06-11 2024-06-21 バイオアークティック アクティエボラーグ 二重特異性結合分子
EP4367516A1 (de) 2021-07-09 2024-05-15 Eisai R&D Management Co., Ltd. Biomarker zur behandlung von morbus alzheimer
AU2022338055A1 (en) 2021-08-30 2024-02-29 Eisai R&D Management Co., Ltd. Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
WO2023111618A1 (en) 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
WO2023114586A1 (en) 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
AU2022439338A1 (en) 2022-02-02 2024-08-15 Eisai R&D Management Co., Ltd. Methods of treatment using p-tau181 level
AU2023406056A1 (en) 2022-11-28 2025-05-01 Eisai R&D Management Co., Ltd. Methods of treatment using a tau pet level
AU2024209632A1 (en) 2023-01-20 2025-05-08 Mabwell Therapeutics, Inc. ANTI-AMYLOID β PROTOFIBRIL/OLIGOMER ANTIBODIES AND USES THEREOF
WO2024254542A1 (en) 2023-06-09 2024-12-12 Eisai R&D Management Co., Ltd. Methods of treatment using an anti-abeta protofibril antibody
WO2025122968A1 (en) 2023-12-06 2025-06-12 Eisai R&D Management Co., Ltd. Predicting mild cognitive impairment based on patient co-morbidities
WO2025137532A1 (en) 2023-12-21 2025-06-26 Eisai R&D Management Co., Ltd. Method for quantifying amyloid beta protofibril

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231000A (en) 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US6174916B1 (en) 1990-04-27 2001-01-16 Milkhaus Laboratory, Ltd. Methods for treating herpes virus infections
ATE153534T1 (de) 1990-04-27 1997-06-15 John Mcmichael Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
EP0730643B1 (de) 1993-10-27 2001-01-10 Elan Pharmaceuticals, Inc. TRANSGENE TIERE, DIE APP Allele mit der schwedischen Mutation beherbergen
DE69521700T2 (de) 1994-05-25 2001-10-25 John Mcmichael Mittel und methoden zur behandlung von plaque-krankheiten
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US6303567B1 (en) 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
EP0815134B1 (de) 1995-03-14 2002-06-05 Praecis Pharmaceuticals Incorporated VERBINDUNGEN MIT AGGREGATIONS-MODULIERENDEN WIRKUNG AUF DAS AMYLOiD PROTEIN
US5854215A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
JPH09178743A (ja) 1995-12-27 1997-07-11 Oriental Yeast Co Ltd 可溶性ａｐｐの定量法
US6054114A (en) 1996-05-08 2000-04-25 Massachusetts Institute Of Technology Organometallic ligands for the localization and quantification of amyloid in vivo and in vitro
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20060178302A1 (en) 1997-02-05 2006-08-10 Northwestern University & The University Of Southern California Amyloid beta protein (globular assembly and uses thereof)
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
ATE306931T1 (de) 1997-12-03 2005-11-15 Neuralab Ltd Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
AU2486900A (en) 1998-12-29 2000-07-31 University Of Georgia Research Foundation, Inc., The Rubredoxin fusion proteins, protein expression system and methods
US6670195B1 (en) 1999-05-26 2003-12-30 New York University Mutant genes in Familial British Dementia and Familial Danish Dementia
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
PE20010212A1 (es) 1999-06-01 2001-02-22 Neuralab Ltd Composiciones del peptido a-beta y procesos para producir las mismas
CA2381323C (en) 1999-08-04 2009-10-06 University Of Southern California Amyloid .beta. protein (globular assembly and uses thereof)
AU784312B2 (en) 1999-11-29 2006-03-09 Bellus Health (International) Limited Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2001090182A2 (en) 2000-05-22 2001-11-29 New York University Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits
WO2002003911A2 (en) * 2000-07-07 2002-01-17 Lars Lannfelt Prevention and treatment of alzheimer's disease
US20030187011A1 (en) 2001-12-20 2003-10-02 Lashuel Hilal A. Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease
KR20040082421A (ko) * 2002-02-11 2004-09-24 제넨테크, 인크. 빠른 항원 결합 속도를 갖는 항체 변이체
EP1497321B1 (de) 2002-04-19 2011-06-29 The Governing Council Of The University Of Toronto Immunologisches verfahren und zusammensetzungen für die behandlung der krankheit von alzheimer
JP2003334075A (ja) * 2002-05-21 2003-11-25 Japan Tobacco Inc 簡便な変異抗体の製造方法
US20040049134A1 (en) 2002-07-02 2004-03-11 Tosaya Carol A. System and methods for treatment of alzheimer's and other deposition-related disorders of the brain
US8871447B2 (en) 2002-09-12 2014-10-28 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
WO2004031400A2 (en) 2002-10-01 2004-04-15 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
CA2504870A1 (en) 2002-11-04 2004-05-21 Bioarctic Neuroscience Ab Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2005011599A2 (en) 2003-08-01 2005-02-10 Northwestern University Antibodies specific for toxic amyloid beta protein oligomers
JP4668191B2 (ja) 2003-08-20 2011-04-13 アモールフィックス・ライフ・サイエンシィズ・リミテッド タンパク質立体配座を検出するためのエピトープ保護アッセイおよび方法
JP2007527865A (ja) 2003-09-12 2007-10-04 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 種々の配列を有するタンパク質から形成されたアミロイドに共通の高分子量凝集中間体に特異的なモノクローナル抗体
SE0400707D0 (sv) 2004-03-22 2004-03-22 Bioarctic Neuroscience Ab Transgenic animal model
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US8507206B2 (en) 2004-07-02 2013-08-13 Northwestern University Monoclonal antibodies that target pathological assemblies of amyloid β (Abeta)
US20060079447A1 (en) * 2004-10-08 2006-04-13 Wetzel Ronald B Stabilized A-beta protofibrillar aggregates
US20080044356A1 (en) 2004-10-22 2008-02-21 Regents Of The University Of Minnesota Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof
KR20070094890A (ko) 2004-10-25 2007-09-27 머크 앤드 캄파니 인코포레이티드 안티 ａｄｄｌ 항체 및 그 용도
WO2006066233A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited An immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies
US20110020237A1 (en) 2005-01-14 2011-01-27 Glabe Charles G Compositions and Methods for Inhibiting Drusen Formation and for Diagnosing or Treating Drusen-Related Disorders
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US7731962B2 (en) 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
AU2006222193B2 (en) 2005-03-05 2011-11-17 AbbVie Deutschland GmbH & Co. KG Screening method, process for purifying of non-diffusible A-beta oligomers, selective antibodies against said non-diffusible A-beta oligomers and a process for manufacturing of said antibodies
WO2006137354A1 (ja) 2005-06-21 2006-12-28 Medical & Biological Laboratories Co., Ltd. アミロイド線維形成に対する阻害活性を有する抗体
TW200726482A (en) 2005-06-30 2007-07-16 Merck & Co Inc Method for preparing a covalently cross linked oligomer of amyloid beta peptides
TW200726774A (en) 2005-06-30 2007-07-16 Merck & Co Inc Composition and method for producing stable amyloid beta oligomers
JP5289963B2 (ja) 2005-10-21 2013-09-11 メルク・シャープ・アンド・ドーム・コーポレーション 抗ａｄｄｌモノクローナル抗体およびその使用
AU2006318537A1 (en) 2005-11-22 2007-05-31 The Trustees Of The University Of Pennsylvania Antibody treatment of Alzheimer's and related diseases
JP5033868B2 (ja) 2006-03-23 2012-09-26 バイオアークティック ニューロサイエンス アーベー 改良型プロトフィブリル選択的抗体及びその使用
ME01026B (me) 2007-11-16 2012-10-20 Univ Rockefeller Antitijela specifična za protofibrilni oblik beta-amiloid proteina
ES2864049T3 (es) 2009-06-29 2021-10-13 Bioarctic Ab Anticuerpos selectivos para protofibrillas/oligómeros de amiloide-P truncado en el extremo N

Also Published As

Publication number Publication date
DK2004688T3 (da) 2011-03-21
CN101421303B (zh) 2013-06-12
EP2325209A2 (de) 2011-05-25
US8025878B2 (en) 2011-09-27
BRPI0709050B1 (pt) 2018-12-26
RU2429244C2 (ru) 2011-09-20
JP2009530374A (ja) 2009-08-27
RS51723B (en) 2011-10-31
KR20080106288A (ko) 2008-12-04
EP2004688B2 (de) 2014-03-05
AU2007227813B2 (en) 2012-09-27
CY1111337T1 (el) 2015-08-05
HK1120056A1 (en) 2009-03-20
HRP20110203T4 (hr) 2014-05-09
US20120076726A1 (en) 2012-03-29
ZA200805805B (en) 2010-09-29
NO347079B1 (no) 2023-05-08
NO2025041I1 (no) 2025-09-05
JP5033868B2 (ja) 2012-09-26
IL191331A (en) 2015-07-30
BRPI0709050A2 (pt) 2011-06-21
CN101421303A (zh) 2009-04-29
US9034334B2 (en) 2015-05-19
KR101413615B9 (ko) 2024-12-18
KR101413615B1 (ko) 2014-07-18
EP2004688A1 (de) 2008-12-24
RU2008141905A (ru) 2010-04-27
CA2630344C (en) 2015-04-28
US20090258009A1 (en) 2009-10-15
PL2004688T3 (pl) 2011-06-30
EP2325209A3 (de) 2011-08-03
RS51723B2 (sr) 2018-03-30
AU2007227813A1 (en) 2007-09-27
NL301343I2 (nl) 2025-10-02
NZ567888A (en) 2010-08-27
SI2004688T2 (sl) 2014-05-30
NO20084445L (no) 2008-10-22
MY169492A (en) 2019-04-15
HRP20110203T1 (en) 2011-04-30
DK2004688T4 (da) 2014-05-12
EP2004688B1 (de) 2010-12-22
FIC20250030I1 (fi) 2025-08-29
CA2630344A1 (en) 2007-09-27
HUS2500037I1 (hu) 2025-09-28
SI2004688T1 (sl) 2011-03-31
PL2004688T5 (pl) 2014-09-30
ATE492561T1 (de) 2011-01-15
WO2007108756A1 (en) 2007-09-27
EP2004688B8 (de) 2011-03-02
MX2008012223A (es) 2008-12-17

Similar Documents

Publication Publication Date Title
ATE492561T1 (de) Verbesserte protofibrilselektive antikörper und deren verwendung
MX2022005782A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos.
WO2006121852A3 (en) Anti-cd19 antibody therapy for autoimmune disease
GB0603683D0 (en) Organic compounds
WO2006089133A8 (en) Anti-cd19 antibodies and uses in oncology
WO2006083964A3 (en) Modified fusion molecules for treatment of allergic disease
CY1115906T1 (el) Ανθρωποποιημενα αντισωματα κατα του βητα αμυλοειδους
WO2007062245A3 (en) Human monoclonal antibody human cd134 (ox40) and methods of making and using same
WO2008060364A3 (en) Humani zed antibody against amyloid beta
ATE435239T1 (de) Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
MX2009013503A (es) Anticuerpo monoclonal anti-amiloide-beta.
WO2008067464A3 (en) NEW Aβ CONFORMER SELECTIVE ANTI-Aβ GLOBULOMER MONOCLONAL ANTIBODIES
WO2006002177A3 (en) Interferon alpha receptor 1 antibodies and their uses
BRPI0410860A (pt) cadeias leve e pesada de imunoglobulina humanizada, imunoglobulina humanizada, anticorpo humanizado, imunoglobulina quimérica, composição farmacêutica, polipeptìdeo isolado, variante de um polipeptìdeo, molécula de ácido nucleico isolada, vetor, célula hospedeira, animal transgênico, uso da seqüência de região variável, kit para formar imagem, composição terapêutica, e, métodos para prevenir ou tratar uma doença amiloidogênica e mal de alzheimer em um paciente, para produzir um anticorpo ou fragmento do mesmo, para identificar resìduos passiveis de substituição, para formar imagem de depósitos de amilóides no cérebro de um paciente, para reduzir carga de placa em um sujeito, para reduzir carga neurìtica em um sujeito, e, para reduzir carga de peptìdeo beta amilóide e distrofia neurìtica em um mamìfero
NO20090156L (no) Humanisert antistoff
PH12011502389B1 (en) Monoclonal antibody
WO2006110214A3 (en) Antibodies against mammalian metapneumovirus
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo
BR112020021855A2 (pt) anticorpo antirrepetição de dipeptídeo (dpr) (poli-ga) derivado de humanos
MXPA03011499A (es) Proteinas de fusion de fce para el tratamiento de alergia y asma.
CY1114604T1 (el) Ανθρωποποιημενο αντισωμα εναντιον αμυλοειδους βητα
WO2007003421A3 (en) Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
IL185653A0 (en) Pharmaceutical compositions containing an antibody which binds the stalk region of kim-1
TNSN08175A1 (en) Human antibodies against il-13 and therapeutic uses
CY1115021T1 (el) Μονοκλωνικα αντισωματα εναντι αμυλοειδους βητα πρωτεϊνης και χρησεις αυτων

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: BIOARCTIC NEUROSCIENCE AB, STOCKHOLM, SE

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载